CN102666538B - 吡咯并吡啶基嘧啶-2-基胺衍生物 - Google Patents

吡咯并吡啶基嘧啶-2-基胺衍生物 Download PDF

Info

Publication number
CN102666538B
CN102666538B CN201080058668.1A CN201080058668A CN102666538B CN 102666538 B CN102666538 B CN 102666538B CN 201080058668 A CN201080058668 A CN 201080058668A CN 102666538 B CN102666538 B CN 102666538B
Authority
CN
China
Prior art keywords
pyridin
pyrrolo
pyrimidin
pyrazol
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080058668.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102666538A (zh
Inventor
M·乌舍尔-普利特凯尔
C·埃斯达尔
B·霍道斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN102666538A publication Critical patent/CN102666538A/zh
Application granted granted Critical
Publication of CN102666538B publication Critical patent/CN102666538B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201080058668.1A 2009-12-23 2010-11-12 吡咯并吡啶基嘧啶-2-基胺衍生物 Expired - Fee Related CN102666538B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009060174.0 2009-12-23
DE102009060174A DE102009060174A1 (de) 2009-12-23 2009-12-23 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
PCT/EP2010/006911 WO2011076316A1 (de) 2009-12-23 2010-11-12 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate

Publications (2)

Publication Number Publication Date
CN102666538A CN102666538A (zh) 2012-09-12
CN102666538B true CN102666538B (zh) 2015-11-25

Family

ID=43531962

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080058668.1A Expired - Fee Related CN102666538B (zh) 2009-12-23 2010-11-12 吡咯并吡啶基嘧啶-2-基胺衍生物

Country Status (10)

Country Link
US (1) US8575163B2 (enExample)
EP (1) EP2516431B1 (enExample)
JP (1) JP5847091B2 (enExample)
CN (1) CN102666538B (enExample)
AR (1) AR079569A1 (enExample)
AU (1) AU2010335628B2 (enExample)
CA (1) CA2785307C (enExample)
DE (1) DE102009060174A1 (enExample)
ES (1) ES2537412T3 (enExample)
WO (1) WO2011076316A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011320565A1 (en) 2010-10-28 2013-05-23 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
DE102010050558A1 (de) * 2010-11-05 2012-05-10 Merck Patent Gmbh 1H-Pyrrolo[2,3-b]pyridinderivate
DE102010053347A1 (de) * 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
EP2760833A1 (en) * 2011-09-30 2014-08-06 Endo Pharmaceuticals Inc. Pyridine derivatives
CN107550905B (zh) * 2017-09-11 2020-07-17 浙江永宁药业股份有限公司 多取代吡咯并吡啶类化合物的药物用途及其制备方法
JP2022507514A (ja) * 2018-11-16 2022-01-18 カリフォルニア インスティチュート オブ テクノロジー Ｅｒｋインヒビター及びその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095400A1 (en) * 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
WO2008155000A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(pyrrolopyridinyl)- pyrimidin-2-yl-amin-derivate und ihre verwendung zur behandlung von krebs und aids
CN102056926A (zh) * 2008-07-03 2011-05-11 默克专利有限公司 吡咯并吡啶基嘧啶-2-基胺衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095400A1 (en) * 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
WO2008155000A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(pyrrolopyridinyl)- pyrimidin-2-yl-amin-derivate und ihre verwendung zur behandlung von krebs und aids
CN102056926A (zh) * 2008-07-03 2011-05-11 默克专利有限公司 吡咯并吡啶基嘧啶-2-基胺衍生物

Also Published As

Publication number Publication date
DE102009060174A1 (de) 2011-06-30
AR079569A1 (es) 2012-02-01
JP2013515685A (ja) 2013-05-09
US8575163B2 (en) 2013-11-05
CA2785307C (en) 2017-10-31
ES2537412T3 (es) 2015-06-08
CN102666538A (zh) 2012-09-12
EP2516431A1 (de) 2012-10-31
CA2785307A1 (en) 2011-06-30
WO2011076316A1 (de) 2011-06-30
US20120270871A1 (en) 2012-10-25
EP2516431B1 (de) 2015-04-15
AU2010335628A1 (en) 2012-08-09
JP5847091B2 (ja) 2016-01-20
AU2010335628B2 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
JP5955902B2 (ja) ピロロピリジニルピリミジン−２−イルアミン誘導体
JP6763904B2 (ja) ピリジン−及びピラジン誘導体
CN105732617B (zh) 7‑氮杂吲哚衍生物
CN101679425B (zh) 6-(吡咯并吡啶基)嘧啶-2-基胺及其治疗癌症和艾滋病的用途
US8664236B2 (en) 1H-pyrrolo[2,3 b]-pyridine derivatives
JP6096797B2 (ja) ３−シアノアリール−１Ｈ−ピラゾロ［２．３−ｂ］ピリジン誘導体
CN102666538B (zh) 吡咯并吡啶基嘧啶-2-基胺衍生物
CN102666544B (zh) 吡咯并[2,3-d]吡嗪-7-基嘧啶化合物
CN104736543A (zh) 用于治疗肿瘤的7-氮杂吲哚-2,7-二氮杂萘衍生物
HK1157766A (en) Pyrrolopyridinylpyrimidin-2-ylamine derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151125

Termination date: 20211112